These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Platelet response to romiplostim amongst patients with newly diagnosed, persistent, and chronic immune thrombocytopenia in routine clinical practice in Denmark, Sweden, and Norway. Christiansen CF, Risbo N, Ghanima W, Linder M, Bahmanyar S, Seesaghur A, Clouser M, Nørgaard M, Sørensen HT. Br J Haematol; 2024 Oct; 205(4):1497-1507. PubMed ID: 39102877 [Abstract] [Full Text] [Related]
7. Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia. Grainger JD, Kühne T, Hippenmeyer J, Cooper N. Ann Hematol; 2021 Sep; 100(9):2143-2154. PubMed ID: 34308495 [Abstract] [Full Text] [Related]
9. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Neunert C, Despotovic J, Haley K, Lambert MP, Nottage K, Shimano K, Bennett C, Klaassen R, Stine K, Thompson A, Pastore Y, Brown T, Forbes PW, Grace RF, Pediatric ITP Consortium of North America (ICON). Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461 [Abstract] [Full Text] [Related]
10. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital. Marquínez-Alonso I, Escudero-Vilaplana V, Pernía S, Beléndez Bieler C, Fernández-Llamazares CM, Sanjurjo-Sáez M. J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274 [Abstract] [Full Text] [Related]
12. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B. Blood; 2011 Oct 20; 118(16):4338-45. PubMed ID: 21832276 [Abstract] [Full Text] [Related]
15. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study. Cooper N, Scully M, Percy C, Nicolson PLR, Lowe G, Bagot CN, Thachil J, Grech H, Nokes T, Hill QA, Bradbury C, Talks K, Dutt T, Evans G, Pavord S, Wexler S, Charania A, Collington SJ, Ervin A, Ramscar N, Provan D. Br J Haematol; 2024 Jun 20; 204(6):2442-2452. PubMed ID: 38429869 [Abstract] [Full Text] [Related]
16. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Mazza P, Minoia C, Melpignano A, Polimeno G, Cascavilla N, Di Renzo N, Specchia G. Ann Hematol; 2016 Jan 20; 95(2):239-44. PubMed ID: 26596973 [Abstract] [Full Text] [Related]
17. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era. Lassandro G, Palladino V, Vecchio GCD, Palmieri VV, Corallo PC, Faienza MF, Giordano P. Endocr Metab Immune Disord Drug Targets; 2021 Jan 20; 21(3):397-406. PubMed ID: 32473624 [Abstract] [Full Text] [Related]